# PH 2 Pemigatinib in SDH-deficient GIST

> **NCT07434843** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 24 (estimated)

## Conditions studied

- SDH Gene Mutation
- Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT07434843
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-10-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07434843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07434843, "PH 2 Pemigatinib in SDH-deficient GIST". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07434843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*